We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
-4.76%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.06B
AUM Growth
+$203M
Cap. Flow
+$295M
Cap. Flow %
27.94%
Top 10 Hldgs %
61.48%
Holding
30
New
7
Increased
14
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$47M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$46.8M
3
ONC
BeOne Medicines Ltd
ONC
+$44.1M
4
ARGX icon
argenx
ARGX
+$33.9M
5
INCY icon
Incyte
INCY
+$32M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$54.3M
2
AKRO
Akero Therapeutics
AKRO
+$33.1M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$20.9M
4
ARVN icon
Arvinas
ARVN
+$20.5M
5
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
+$8.17M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
1
Biogen
BIIB
$29.9B
$97.2M 9.21%
349,593
+110,821
+46% +$30.7M
INCY icon
2
Incyte
INCY
$23.5B
$91.2M 8.64%
1,261,711
+408,881
+48% +$32M
LEGN icon
3
Legend Biotech
LEGN
$4.3B
$72.8M 6.9%
1,510,324
+455,454
+43% +$22.3M
ARGX icon
4
argenx
ARGX
$57.4B
$67.5M 6.4%
181,172
+91,616
+102% +$33.9M
SGEN
5
DELISTED
Seagen Inc. Common Stock
SGEN
$57.1M 5.41%
281,969
-4,319
-2% -$693K
IMCR icon
6
Immunocore
IMCR
$1.78B
$55.7M 5.28%
1,126,256
+268,331
+31% +$15.1M
ACLX
7
DELISTED
Arcellx
ACLX
$54.2M 5.13%
1,757,779
+875,678
+99% +$26.6M
VRDN icon
8
Viridian Therapeutics
VRDN
$2.13B
$53.1M 5.03%
2,085,698
+334,531
+19% +$10.7M
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$51.9M 4.92%
1,396,779
+128,809
+10% +$5.79M
SNDX icon
10
Syndax Pharmaceuticals
SNDX
$1.84B
$48M 4.55%
2,274,512
+320,000
+16% +$7.96M
UTHR icon
11
United Therapeutics
UTHR
$26.3B
$47.5M 4.5%
211,892
+63,000
+42% +$15.5M
KROS icon
12
Keros Therapeutics
KROS
$199M
$39.7M 3.77%
+930,752
New +$47M
ONC
13
BeOne Medicines Ltd
ONC
$33.8B
$39.7M 3.76%
+184,012
New +$44.1M
CERE
14
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$38.9M 3.69%
+1,595,199
New +$46.8M
BCYC
15
Bicycle Therapeutics
BCYC
$270M
$38.6M 3.66%
1,816,781
+583,501
+47% +$14.6M
ASND icon
16
Ascendis Pharma A/S
ASND
$16.7B
$37.6M 3.57%
350,866
-1,942
-0.6% -$222K
VOR icon
17
Vor Biopharma
VOR
$1.04B
$34.9M 3.3%
323,900
+1,759
+0.5% +$195K
ZLAB icon
18
Zai Lab
ZLAB
$2.17B
$26M 2.46%
780,558
+265,284
+51% +$10.2M
XENE icon
19
Xenon Pharmaceuticals
XENE
$6.32B
$23.3M 2.21%
+651,068
New +$24.1M
VRNA
20
DELISTED
Verona Pharma
VRNA
$19.3M 1.83%
+962,361
New +$20.8M
CRNX icon
21
Crinetics Pharmaceuticals
CRNX
$8.86B
$18.2M 1.73%
1,133,782
+243,677
+27% +$4.51M
ALPN
22
DELISTED
Alpine Immune Sciences Inc
ALPN
$17.9M 1.7%
2,317,634
– –
THRX
23
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$13.4M 1.27%
+1,505,327
New +$14.8M
OLMA icon
24
Olema Pharmaceuticals
OLMA
$1.02B
$8.27M 0.78%
+2,382,377
New +$9.72M
PSTX
25
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$3.3M 0.31%
1,072,410
-1,362,406
-56% -$8.17M
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
WTC
WhitTier Trust Company Reno, Nevada $4.87B AUM 25.35% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MSRPS
Maryland State Retirement & Pension System Baltimore, Maryland $4.92B AUM 28.48% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return

Paradigm Biocapital Advisors's Q1 2023 Portfolio in Review

As of Q1 2023, Paradigm Biocapital Advisors held 30 positions worth $1.06B, up 24% from $852M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Paradigm Biocapital Advisors deployed $295M of net new capital in Q1 2023, opening 7 new positions and adding to 14 existing holdings. Its largest new stake was Keros Therapeutics: 930,752 shares worth $39.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Poseida Therapeutics, Inc. Common Stock, an estimated $8.17M trimmed.

  • Paradigm Biocapital Advisors's largest Q1 2023 buy was Keros Therapeutics: 930,752 shares worth $39.7M.
  • Paradigm Biocapital Advisors added most to argenx in Q1 2023, an estimated $33.9M increase.
  • Paradigm Biocapital Advisors's biggest Q1 2023 reduction was Poseida Therapeutics, Inc. Common Stock, cutting an estimated $8.17M.
  • Paradigm Biocapital Advisors fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, selling an estimated $54.3M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 61% of its $1.06B portfolio in Q1 2023.
  • Paradigm Biocapital Advisors opened 7 new positions and closed 5 in Q1 2023.
  • Paradigm Biocapital Advisors's portfolio value rose 24% quarter-over-quarter to $1.06B.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2023, filed 15 May 2023.